- Home
- TRX vs CTOR Comparison
TRX vs CTOR Comparison
Compare TRX & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRX
- CTOR
- Stock Information
- Founded
- TRX 1990
- CTOR 2021
- Country
- TRX Canada
- CTOR United States
- Employees
- TRX N/A
- CTOR N/A
- Industry
- TRX
- CTOR
- Sector
- TRX
- CTOR
- Exchange
- TRX Nasdaq
- CTOR NYSE
- Market Cap
- TRX 90.0M
- CTOR 63.7M
- IPO Year
- TRX N/A
- CTOR N/A
- Fundamental
- Price
- TRX $0.32
- CTOR $4.29
- Analyst Decision
- TRX Strong Buy
- CTOR Buy
- Analyst Count
- TRX 1
- CTOR 2
- Target Price
- TRX $1.50
- CTOR $6.00
- AVG Volume (30 Days)
- TRX 445.0K
- CTOR 3.1M
- Earning Date
- TRX 07-22-2025
- CTOR 08-11-2025
- Dividend Yield
- TRX N/A
- CTOR N/A
- EPS Growth
- TRX N/A
- CTOR N/A
- EPS
- TRX N/A
- CTOR N/A
- Revenue
- TRX $45,405,000.00
- CTOR N/A
- Revenue This Year
- TRX $51.45
- CTOR N/A
- Revenue Next Year
- TRX $26.19
- CTOR N/A
- P/E Ratio
- TRX N/A
- CTOR N/A
- Revenue Growth
- TRX 26.50
- CTOR N/A
- 52 Week Low
- TRX $0.27
- CTOR $0.55
- 52 Week High
- TRX $0.45
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- TRX 47.94
- CTOR N/A
- Support Level
- TRX $0.33
- CTOR N/A
- Resistance Level
- TRX $0.36
- CTOR N/A
- Average True Range (ATR)
- TRX 0.01
- CTOR 0.00
- MACD
- TRX -0.00
- CTOR 0.00
- Stochastic Oscillator
- TRX 3.54
- CTOR 0.00
About TRX TRX Gold Corporation
TRX Gold Corp is a mineral resource company. It is engaged in the acquisition of interests and the exploration of natural resource properties. Its mineral properties are located in the United Republic of Tanzania. The company's main area of interest has been in the exploration and development of gold properties. It is focused on the Buckreef Gold Project which comprises five prospects, namely Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba.
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.